Home » Topics » Drug design, drug delivery and technologies, BioWorld Science

Drug design, drug delivery and technologies, BioWorld Science
RSS

Competitive Technologies and Mount Sinai School of Medicine sign agreement

June 21, 1996

Cheung Laboratories and MIT reach marketing agreement

June 21, 1996

Zeneca to utilize Incyte database and technologies

June 21, 1996

RPR Gencell and IntraImmune Therapies enter drug development agreement

June 21, 1996

Megabios issued worldwide license to lipid-DNA complexes

June 21, 1996

Drug development agreement reached by Megabios and Pfizer

June 21, 1996

HemaSure/American Red Cross Biomedical Services alliance

June 14, 1996

Exelixis acquires rights to P Element technology

June 14, 1996

Bayer/CV Therapeutics antiinflammatory drug agreement

June 14, 1996

Bristol-Myers Squibb/Garvan Institute of Medical Research collaboration

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.